This symposium will provide a cutting edge update on what leads to psychosis in dementia and how to treat it better. Professor Suzanne Reeve will talk about her work which won the 2022 Rob Kerwin Psychopharmacology Committee Prize for the best paper published in the British Journal of Psychiatry in 2022. This will cover improving the safety of treatment of psychosis in dementia through understanding the pharmacokinetic and pharmacodynamic contributions to antipsychotic drug sensitivity in people with Alzheimer's (based on NIHR funded PET D2 receptor imaging study) and the TOP HAT trial of ondansetron as a Parkinson's Hallucinations Treatment.
Dr Emma McLachlan, South London and Maudsley NHS Trust, will talk about the cognitive and neuroanatomical basis of psychosis in dementia, and the potential for cognitive interventions. And finally Professor Lon Schneider will cover the evidence of efficacy, safety and risk of harm associated with second generation antipsychotic drug treatment of psychosis in people with dementia (including CATIE-AD) and the role of novel agents such as pimavanserin in the treatment of Parkinson's psychosis and relevance for other neurodegenerative disorders
- In this session you will gain:
- An understanding of the pharmacokinetic and pharmacodynamic contributions to antipsychotic drug sensitivity in people with Alzheimer's.
- An understanding of the evidence of efficacy, safety and risk of harm associated with second generation antipsychotic drug treatment of psychosis in people with dementia.
- An understanding of the role of false recognition in the development of psychosis in dementia.
Chair: Professor Rob Howard, UCL Division of Psychiatry
Emma McLachlan, South London and Maudsley NHS Trust, United Kingdom
Lon Schneider, University of Southern California, Los Angeles, USA
Suzanne Reeves, University College London, United Kingdom
